CytomX initiates treatment in Phase I/II trial of CX-072 for cancer therapy

5th February 2017 (Last Updated February 5th, 2017 18:30)

US-based bio-pharmaceutical company CytomX Therapeutics has initiated treatment in a Phase I/II trial (PROCLAIM-072) of CX-072 to treat patients with any type of cancer.

US-based bio-pharmaceutical company CytomX Therapeutics has initiated treatment in a Phase I/II trial (PROCLAIM-072) of CX-072 to treat patients with any type of cancer.

CX-072 is a PD-L1 designed to target Probody therapeutic as a monotherapy or in combination with Yervoy (ipilimumab) or Zelboraf (vemurafenib).

The open-label, dose-finding Phase I/II study is part of the firm's PROCLAIM (Probody Clinical Assessment In Man) programme and will evaluate tolerability and anti-cancer activity of CX-072.

CytomX Therapeutics chief medical officer Rachel Humphrey said: “Treating the first patient with CX-072 marks a key milestone as we advance our broad pipeline of innovative Probody therapeutics into clinical development within the PROCLAIM programme.

"Treating the first patient with CX-072 marks a key milestone as we advance our broad pipeline of innovative Probody therapeutics into clinical development within the PROCLAIM programme."

“Advancement of this potentially transformational treatment, derived from our Probody technology platform, would not be possible without the patients who are willing to engage with the scientific community by enrolling in clinical trials. We thank them for their participation.”

The trial will assess the tolerance and safety of the drug in the patients primarily as combination therapy, in addition to establishing initial evidence of CX-072’s anti-cancer activity both as a monotherapy and in combination.

The firm aims to further establish a translational programme and Probody platform proof-of-concept through the Phase I/II study.

Based on its Probody technology platform, CytomX develops investigational antibody therapeutics and cancer immunotherapies against clinically validated targets.

The developed Probody therapeutics are expected to act on the tumour microenvironment to increase the tumour-targeting properties of an antibody and decrease drug activity in healthy tissues.